MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced it will present one-year clinical outcomes from the 2,400 patient INFINITY-SWEDEHEART Randomized Clinical Trial (RCT), a prospective, multi-center, single-blind, clinical trial comparing the drug-eluting DynamX Coronary Bioadaptor System with the contemporary Resolute OnyxTM zotarolimus drug-eluting stent (DES), at a late-breaking Hot […]
Tag: DES
Medtronic Launches First 2.0 mm Drug-Eluting Stent in United States Designed to Treat Patients with Small Vessels
FDA Approved, Resolute Onyx 2.0 mm DES Technology Tackles Clinical Challenge of Treating Coronary Artery Disease in Previously Untreatable Patients DUBLIN – February 26, 2018 – Designed specifically for small vessels, Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute Onyx(TM) 2.0 mm Drug-Eluting Stent […]
Study Validates New Approach for Optimizing Endovascular Drug Delivery Using Stents with a Deployable Coating That Enhances Sirolimus Distribution Compared to Traditional DES
“This preclinical demonstration that stent deployment of microcrystalline drug in combination with a rapidly absorbable polymer, such as with MiStent, results in more uniform drug dosing that could lead to more rapid and uniform healing across the treated segment,” said David Kandzari, M.D., Director of Interventional Cardiology and Chief Scientific Officer, Piedmont Heart Institute, Atlanta. LEXINGTON, Mass.–(BUSINESS […]
Cordis/Medinol DES implanted in the U.S.
N.Y. Presbyterian/Columbia implant EluNIR stent Cordis and Medinol Announce First U.S. Commercial Implants of Innovative EluNIR™ Drug-Eluting Stent – by CardiovascularBusiness DUBLIN, Ohio, January 11, 2018 — Cordis, a Cardinal Health company, and Medinol today announced that the first commercial cases using the EluNIR™ drug-eluting stent (DES) in the United States were performed at New York-Presbyterian […]
Svelte Medical Systems Announces First Patient Enrolled in Pivotal OPTIMIZE Study
NEW PROVIDENCE, N.J.–(BUSINESS WIRE)– The Christ Hospital, Lindner Research Center in Cincinnati, Ohio, enrolled the first patient in Svelte Medical System’s OPTIMIZE clinical study, designed to further assess the safety and effectiveness of the Svelte Drug-Eluting Stent (DES) Integrated Delivery System (IDS) and Rapid Exchange (RX) platforms. The randomized, controlled OPTIMIZE study is expected to […]
Cordis and Medinol Announce FDA Approval of the Innovative EluNIR Drug-Eluting Stent System
DUBLIN, Ohio, Nov. 30, 2017 /PRNewswire/ — Cordis, a Cardinal Health company, and Medinol today announced United States Food and Drug Administration (FDA) approval of the EluNIR™ drug-eluting stent (DES) for the treatment of patients with narrowing or blockages to their coronary arteries. The EluNIR™ stent system is designed with a novel metallic spring tip and the narrowest […]
Postmarket Surveillance Study Confirms Benefits of Cook Medical’s Zilver® PTX® Drug Eluting Stent at 12 Months in Japanese Patients
LAS VEGAS–(BUSINESS WIRE)–One-year post-market surveillance (PMS) study data from Japanese patients who received the Zilver® PTX® drug-eluting stent confirmed the benefits of the device at 12 months, researchers announced today. Japanese researchers presented the PMS study results at themeeting in Las Vegas. This was the first time the study has been presented in the United States. The […]
TCT 2017: BIOTRONIK Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
Denver, United States / Buelach, Switzerland, 31.10.2017 (PresseBox) – Data presented at the BIOTRONIK-sponsored symposium on the Orsiro1 drug-eluting stent (DES) demonstrate why Orsiro is gaining prominence in the crowded DES market. In addition, clinical and preclinical data presented about Magmaris2 reinforce the case that the magnesium-based resorbable technology does not share the same risk of acute and late scaffold thrombosis […]
OrbusNeich’s COMBO Dual Therapy Stent Demonstrates Non-Inferiority vs the Market Leading XIENCE™ Everolimus Eluting Stent
DENVER, October 30, 2017 /PRNewswire/ — New results from the HARMONEE Japan/US Registration Trial, reported by OrbusNeich today in the First Report Investigations session at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrate that the COMBO(TM) Dual Therapy Stent (DTS) compares favorably to the market leading option for treating patients with significant ischemic heart disease. […]
Abbott Introduces Next Generation of Most Widely Used Heart Stent for People With Coronary Artery Disease in Europe
ABBOTT PARK, Ill., Oct. 30, 2017 /PRNewswire/ — Abbott today announced it received CE Mark for XIENCE Sierra, the newest generation of the company’s gold-standard XIENCE everolimus-eluting coronary stent system. CE Mark allows sale of the device in the European Union and other countries that recognize CE Mark. Advances in this generation of XIENCE — which is […]
Recent
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
Reprieve Cardiovascular Builds Clinical Momentum with Positive Results from FASTR Pilot Trial and FDA Investigational Device Exemption Approval for Pivotal Trial
BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM
Popular
- No commented posts yet